NCT05491616View on ClinicalTrials.gov

Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Esophageal Cancer

Interventions

DRUG

Nivolumab

In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.

Trial Locations (1)

3015GD

Erasmus MC, Rotterdam